Adaptive Biotechnologies
ADPT
187 hedge funds and large institutions have $732M invested in Adaptive Biotechnologies in 2024 Q3 according to their latest regulatory filings, with 32 funds opening new positions, 66 increasing their positions, 44 reducing their positions, and 20 closing their positions.
60% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 20
56% more call options, than puts
Call options by funds: $403K | Put options by funds: $259K
50% more repeat investments, than reductions
Existing positions increased: 66 | Existing positions reduced: 44
36% more capital invested
Capital invested by funds: $538M → $732M (+$194M)
6% more funds holding
Funds holding: 176 → 187 (+11)
3.84% less ownership
Funds ownership: 100.88% → 97.04% (-3.8%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BWLSA
Blue Water Life Science Advisors
Larkspur,
California
|
+$9.35M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
+$3.63M |
| 3 |
NAMA
Nikko Asset Management Americas
New York
|
+$3.55M |
| 4 |
Goldman Sachs
New York
|
+$3.05M |
| 5 |
CC
Clearline Capital
New York
|
+$2.68M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
-$47.6M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$4.49M |
| 3 |
TC
Tejara Capital
London,
United Kingdom
|
-$3.29M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
-$2.65M |
| 5 |
Jane Street
New York
|
-$2.25M |
ADPT Hedge Fund Activity: Q3 2024 in Review
187 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Adaptive Biotechnologies (ADPT) for Q3 2024, worth a combined $732M — up 36% from $538M a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new ADPT positions and 20 closed out — a net gain of 12 holders — while 66 added to existing stakes and 44 trimmed.
The largest buyer was Blue Water Life Science Advisors, opening a new position worth an estimated $9.35M. The largest seller was Matrix Capital Management Company, cutting an estimated $47.6M.
- 187 institutional investors held Adaptive Biotechnologies (ADPT) as of Q3 2024, up from 176 in Q2 2024.
- Funds reported $732M of Adaptive Biotechnologies stock for Q3 2024, up 36% quarter-over-quarter.
- 32 funds opened new Adaptive Biotechnologies positions in Q3 2024 and 20 closed out, a net change of +12 holders.
- The largest Adaptive Biotechnologies buyer in Q3 2024 was Blue Water Life Science Advisors, an estimated $9.35M added.
- The largest Adaptive Biotechnologies seller in Q3 2024 was Matrix Capital Management Company, an estimated $47.6M sold.
Based on aggregated 13F filings for Q3 2024.